CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer
Alterations in the PI3K/AKT/mTOR and JUN pathways can induce resistance to multiple combinations of MAPK pathway inhibitors, and may serve as biomarkers for sensitivity/resistance in clinical trials exploring such combinations in KRAS-mutant PDAC.
Authors
- Sara Mainardi (ORCID: https://orcid.org/0000-0001-7255-6153)
- R. Bernards
- Astrid Bosma (ORCID: https://orcid.org/0000-0003-3776-3215)
- Manon Boeije
- Antonio Mulero‐Sánchez (ORCID: https://orcid.org/0000-0003-1668-7022)
- Cor Lieftink (ORCID: https://orcid.org/0000-0002-2754-4150)
- Niki Pouliopoulou
- Bonifiya Visuvasam
- Natalie Proost
- Roderick Beijersbergen
- Marieke van de Ven
Institutions
- Oncode Institute (NL)
- Cancer Genomics Centre (NL)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1186/s13046-025-03616-z
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.00